Abstract: Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I)

Abstract: Described herein are compounds of formula (I) useful as antagonists of tachykinins in general, and in particular of neurokinin A; and the pharmaceutical formulations comprising the compounds of formula (I) 1

Abstract: An improvement is described in the synthesis method for N.sup..alpha. -trityl-N.sup.G -trityl arginine within a process for preparing N.sup..alpha. -fluorenylmethoxycarbonyl-N.sup.G -trityl-arginine from arginine, comprising:a) forming N.sup..alpha. -trityl-N.sup.G -trityl-arginineb) selectively detaching the trityl group from the .alpha.-NH.sub.2 andc) introducing the fluorenylmethoxycarbonyl group in its place.The improvement consists of preparing the N.sup..alpha. -trityl-N.sup.G -trityl-arginine by solubilizing the arginine in an aprotic organic solvent by tri-alkylsilylation both of the amino nitrogen and of the carboxyl group, followed by tritylation, with trityl chloride, of the .alpha.-amino nitrogen, and of the guanidino group after deprotonating this latter with a bicyclic guanidine. The new improved process can also lead to variable quantities of the arginine analogue di-tritylated at the guanidino group, namely N.sup..alpha. -fluorenylmethoxycarbonyl-N.sup.G -di-trityl-arginine.

Abstract: A method is described for substituting at least one hydrogen atom originally present in the guanidino group of a compound of general formula (I) ##STR1## where R is any substituted or unsubstituted residue, by a group R.sub.1 where R.sub.1 is an unsubstituted or substituted, linear or branched alkyl, consisting of:a) silylating the guanidino group and any other silylatable functional groups present within the R group andb) alkylating the product obtained in step a) with a mixture consisting of the alkyl halide R.sub.1 -X and an organic base containing a tertiary nitrogen.

Abstract: An improvement is described in the synthesis method for N.sup..alpha. -trityl-N.sup.G -trityl arginine within a process for preparing N.sup..alpha. -fluorenyl-methoxycarbonyl-N.sup.G -trityl-arginine from arginine, comprising:a) forming N.sup..alpha. -trityl-N.sup.G -trityl-arginineb) selectively detaching the trityl group from the .alpha.-NH.sub.2 andc) introducing the fluorenylmethoxycarbonyl group in its place.The improvement consists of preparing the N.sup..alpha. -trityl-N.sup.G -trityl-arginine by solubilizing the arginine in an aprotic organic solvent by tri-alkylsilylation both of the amino nitrogen and of the carboxyl group, followed by tritylation, with trityl chloride, of the .alpha.-amino nitrogen, and of the guanidino group after deprotonating this latter with a bicyclic guanidine. The new improved process can also lead to variable quantities of the arginine analogue di-tritylated at the guanidino group, namely N.sup..alpha. -fluorenylmethoxycarbonyl-N.sup.G -di-trityl-arginine.

Abstract: New decapeptides having hypotensive action are disclosed, which can be defined by the formula:GLp-Leu-Trp-Pro-X-Pro-Y-Z-Pro-Pro-OH (I)wherein:X=Arg or OrnY=His or GlnZ=Ile or Valwith the following limitations:whenX=Arg:Y=HisZ=Val;whenX=Orn:Y=GlnZ=Ile;or, whenX=Orn:Y=HisZ=Valand pharmaceutically acceptable salts, amides of alkyl esters thereof.

Abstract: A dioldione represented by the formula: ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, the same or different, represent alkyl, cycloalkyl, arylalkyl, aryl or hydrogen, is prepared by reacting a compound represented by the formula: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 have the above meanings, with an oxidizing mixture consisting of osmium tetroxide and an alkali or alkali-earth metal chlorate.